Medication for Opioid Use Disorder (MOUD): Critical Considerations for Your Jail Facility
7/28/23 at 10:00 AM to 7/28/23 at 11:00 AM
More than 30% of people incarcerated in jails suffer from serious opioid withdrawal or inability to control their opioid use. Left untreated, opioid use disorder can be fatal and puts the facility and its leaders at considerable risk.
One solution is Medications for Opioid Use Disorder (MOUD) – a program that goes far beyond management of initial withdrawal symptoms. MOUD, sometimes referred to as Medication-Assisted Treatment (MAT), is considered the standard of care for incarcerated individuals with opioid use disorder and can help patients manage their substance use disorder and, in turn, reduce recidivism. Yet many jail and correctional facility administrators are unsure how to develop MOUD programs that are safe, legal and effective.
Join Lexipol and the National Commission on Correctional Health Care (NCCHC) to learn why and how your facility can save lives through a well-developed MOUD program.
You’ll learn:
- Essential information on FDA-approved medications buprenorphine, methadone, and naltrexone and their use in correctional environments.
- The foundations of the movement toward jail-based MOUD, including legal obligations and medication effectiveness.
- Key components of a successful MOUD program.
- How to address common challenges such as medication diversion, regulatory restrictions, and obtaining stakeholder buy-in.
Speakers: Robert M. Simon Jr., MEd, LPC-S, NCC, CCHP and Richard Forbus, CCHP